Skip to main content

Advertisement

Table 2 Incidence of solicited local adverse events per vaccine type per dose

From: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

   First dose Second dose Third dose
   15 μg MSP3 30 μg MSP3 Engerix B 15 μg MSP3 30 μg MSP3 Engerix B 15 μg MSP3 30 μg MSP3 Engerix B
   N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15 N = 15
Symptom Intensity n % n % n % n % n % n % n % n % n %
Any Overall 8 53 10 67 7 47 12 80 6 40 6 40 9 60 12 80 9 60
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pain Overall 3 20 2 13 1 6.7 1 6.7 1 6.7 1 6.7 0 0 1 6.7 2 13
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Swelling Overall 3 20 7 47 5 33 4 27 1 6.7 1 6.7 3 20 2 13 3 20
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Erythema Overall 0 0 2 13 1 6.7 1 6.7 1 6.7 1 6.7 1 6.7 0 0 2 13
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Induration Overall 8 53 10 67 6 40 12 80 7 47 6 40 8 53 12 80 8 53
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pruritus Overall 0 0 0 0 0 0 0 0 0 0 1 6.7 0 0 0 0 0 0
  Grade 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0